AVBP – arrivent biopharma, inc. (US:NASDAQ)
Stock Stats
News
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476M [Seeking Alpha]
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products [Yahoo! Finance]
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab [Yahoo! Finance]
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
Form 8-K ArriVent BioPharma, Inc. For: Jun 04
Form 4 ArriVent BioPharma, Inc. For: May 16 Filed by: Hohneker John
Form 3 ArriVent BioPharma, Inc. For: May 16 Filed by: Hohneker John
Form 8-K ArriVent BioPharma, Inc. For: May 16
Form 10-Q ArriVent BioPharma, Inc. For: Mar 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.